«Super-Killer SARS-COV-2» fra Boston


Jeg håper ikke dette nye viruset «slipper ut», men kommer det til Europa vil nok Bemcentinib ta knekken på dette også.

https://open.substack.com/pub/viralimmunologist/p/lab-in-boston-made-what-could-be?r=1gsxwe&utm_campaign=post&utm_medium=email


https://open.substack.com/pub/viralimmunologist/p/lab-in-boston-made-what-could-be?utm_source=direct&utm_campaign=post&utm_medium=web


I was in shock when a couple of my colleagues directed me to a pre-print article that was posted online on Friday October 14, 2022. Pre-prints are scientific papers that have not yet undergone peer review and they have not been published in a journal. In this case, these nuances are moot. What is far more important is the product that has been described, along with the disclosure of the recipe to make it.

You can find the pre-print article at this link.

Here is the full citation:

Title: “Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron”

Authors: Da-Yuan Chen, Devin Kenney, Chue Vin Chin, Alexander H. Tavares, Nazimuddin Khan, Hasahn L. Conway, GuanQun Liu, Manish C. Choudhary, Hans P. Gertje, Aoife K. O’Connell, Darrell N. Kotton, Alexandra Herrmann, Armin Ensser, John H. Connor, Markus Bosmann, Jonathan Z. Li, Michaela U. Gack, Susan C. Baker, Robert N. Kirchdoerfer, Yachana Kataria, Nicholas A. Crossland, Florian Douam, Mohsan Saeed

bioRxiv 2022.10.13.512134

doi: https://doi.org/10.1101/2022.10.13.512134

Redigert 18.10.2022 kl 10:37 Du må logge inn for å svare
BioBull
18.10.2022 kl 21:03 1108

Flere nye varianter COVID dukker nå opp forskjellige steder i verden.

Bemcentinib fra BerGenBio vil høyst sannsynligvis hjelpe mange syke mennesker.

« The two descendants of omicron’s BA.5 subvariant, called BQ.1 and BQ.1.1, both have dangerous “qualities or characteristics that could evade some of the interventions we have,” Fauci told CBS News on Friday. The two sublineages are responsible for more than 10% of all current U.S. cases, according to the latest Centers for Disease Control and Prevention data — just one week after they weren’t even significant enough to list.»

tobo581
18.10.2022 kl 22:33 981

Høyst sannsynlig... Eller ønskelig om man er aksjonær i BGBIO.
Penga og makten rår.
Pharma er big, har lobbyister og styrer festen.
Sterk i troen jeg også
JanH
19.10.2022 kl 11:00 629

Vi ser hvor mye dette påvirker kursen i BergenBio. Negativ kurs på positiv børs i dag.

Ingen….løper skoene av seg for å handle i dag heller.